v3.25.1
Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details) - USD ($)
3 Months Ended
Feb. 21, 2025
Mar. 31, 2025
Mar. 31, 2024
Research and development (excluding share-based compensation) expense:      
PAH   $ 9,330,844 $ 0
Parkinson's disease   142,420 2,343,896
Other programs   587,128 389,453
Selling, general and administrative (excluding share-based compensation)   3,660,282 1,995,577
Change in fair value contingent consideration $ 4,435,443 (1,164,864) 0
Share-based compensation expense   2,042,196 53,434
Total costs and expenses   14,598,006 4,782,360
Loss from operations   (14,598,006) (4,782,360)
Interest income   919,271 132,725
Net loss   (13,678,735) (4,649,635)
Operating Segment      
Research and development (excluding share-based compensation) expense:      
Share-based compensation expense   $ 2,042,196 $ 53,434